{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T22:25:32Z","timestamp":1747779932769},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1993,2,1]],"date-time":"1993-02-01T00:00:00Z","timestamp":728524800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[1993,2]]},"DOI":"10.1007\/bf02251286","type":"journal-article","created":{"date-parts":[[2005,11,15]],"date-time":"2005-11-15T13:43:55Z","timestamp":1132062235000},"page":"309-319","source":"Crossref","is-referenced-by-count":28,"title":["The discriminative stimulus properties of legal, over-the-counter stimulants administered singly and in binary and ternary combinations"],"prefix":"10.1007","volume":"110","author":[{"given":"David V.","family":"Gauvin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle R.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley D.","family":"Youngblood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank A.","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02251286_CR1","first-page":"30","volume":"7","author":"LV Allen","year":"1982","unstructured":"Allen LV (1982) Turkey drugs \u2014 what you see is not what you get. US Pharm 7:30\u201339","journal-title":"US Pharm"},{"key":"BF02251286_CR2","first-page":"549","volume":"6","author":"S Altschuler","year":"1982","unstructured":"Altschuler S, Conte A, Sebok M, Marlin RL, Winick C (1982) Three controlled trials of weight loss with phenylpropanolamine. J Obes 6:549\u2013556","journal-title":"J Obes"},{"key":"BF02251286_CR3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/ddr.430160230","volume":"16","author":"JE Barrett","year":"1989","unstructured":"Barrett JE, Olmstead SN (1989) Spiroxatrine as a discriminative stimulus effects depend on pharmacological history. Drug Dev Res 16:365\u2013374","journal-title":"Drug Dev Res"},{"key":"BF02251286_CR4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0160-3450(16)33105-1","volume":"11","author":"JR Boyd","year":"1986","unstructured":"Boyd JR (1986) Pseudoephedrine. Am Pharm 11:22\u201324","journal-title":"Am Pharm"},{"key":"BF02251286_CR5","first-page":"212","volume":"96","author":"LD Chait","year":"1988","unstructured":"Chait LD, Uhlenhuth EH, Johanson CE (1988) Phenylpropanolamine: reinforcing and subjective effects in normal volunteers. Psychopharmacology 96:212\u2013217","journal-title":"Psychopharmacology"},{"key":"BF02251286_CR6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0010-0285(70)90016-2","volume":"1","author":"WR Garner","year":"1970","unstructured":"Garner WR, Felfoldy GL (1970) Integrality of stimulus dimensions in various types of information processing. Cog Psychol 1:225\u2013241","journal-title":"Cog Psychol"},{"key":"BF02251286_CR7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0024-3205(89)90219-1","volume":"44","author":"DV Gauvin","year":"1989","unstructured":"Gauvin DV, Harland RD, Michaelis RC, Holloway FA (1989) Caffeine-phenylethylamine combinations mimic the cocaine discriminative cue. Life Sci 44:67\u201373","journal-title":"Life Sci"},{"key":"BF02251286_CR8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev.me.40.020189.001053","volume":"40","author":"FH Gawin","year":"1989","unstructured":"Gawin FH, Ellinwood EH Jr (1989) Cocaine dependence. Annu Rev Med 40:149\u2013161","journal-title":"Annu Rev Med"},{"key":"BF02251286_CR9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/archpsyc.1986.01800020013003","volume":"43","author":"FH Gawin","year":"1986","unstructured":"Gawin FH, Kleber HD (1986) Abstinence symptomatology and psychiatric diagnosis in cocaine abusers: Clinical observations. Arch Gen Psychiatry 43:107\u2013113","journal-title":"Arch Gen Psychiatry"},{"key":"BF02251286_CR10","first-page":"165","volume-title":"Phenylpropanolamine: risks, benefits, and controversies","author":"JF Greden","year":"1985","unstructured":"Greden JF (1985) The relationship between phenylpropanolamine and caffeine. In: Morgan JP, Kagan DV, Brody JS (eds). Phenylpropanolamine: risks, benefits, and controversies. Praeger Scientific, New York, pp 165\u2013179"},{"key":"BF02251286_CR11","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/0091-3057(89)90075-0","volume":"32","author":"RD Harland","year":"1989","unstructured":"Harland RD, Gauvin DV, Michaelis RC, Carney JM, Seale TW, Holloway FA (1989) Behavioral interaction between cocaine and caffeine: a drug discrimination analysis in rats. Pharmacol Biochem Behav 32:1017\u20131023","journal-title":"Pharmacol Biochem Behav"},{"key":"BF02251286_CR12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ddr.430160213","volume":"16","author":"FA Holloway","year":"1989","unstructured":"Holloway FA, Gauvin DV (1989) Comments on method and theory in drug discrimination: a potpouri of problems, perplexities, and possibilites. Drug Dev Res 16:195\u2013207","journal-title":"Drug Dev Res"},{"key":"BF02251286_CR13","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/0024-3205(85)90191-2","volume":"36","author":"FA Holloway","year":"1985","unstructured":"Holloway FA, Michaelis RC, Huerta PL (1985) Caffeine-phenylethylamine combinations mimic the amphetamine discriminative cue. Life Sci 36:723\u2013730","journal-title":"Life Sci"},{"key":"BF02251286_CR14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3758\/BF03212473","volume":"2","author":"R Hyman","year":"1967","unstructured":"Hyman R, Well A (1967) Judgments of similarity and spatial models. Percept Psychophys 2:233\u2013248","journal-title":"Percept Psychophys"},{"key":"BF02251286_CR15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3758\/BF03212721","volume":"3","author":"R Hyman","year":"1968","unstructured":"Hyman R, Well A (1968) Perceptual separability and spatial models. Percept Psychophys 3:161\u2013165","journal-title":"Percept Psychophys"},{"key":"BF02251286_CR16","volume-title":"Experimental design: procedures for the behavioral sciences","author":"RE Kirk","year":"1982","unstructured":"Kirk RE (1982) Experimental design: procedures for the behavioral sciences. Brooks\/Cole Publishing Monterey, CA"},{"key":"BF02251286_CR17","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/clpt.1990.93","volume":"47","author":"CR Lake","year":"1990","unstructured":"Lake CR, Rosenberg DB, Gallant S, Zaloga G, Chernow B (1990) Phenylpropanolamine increases plasma caffeine levels. Clin Pharmacol Ther 47:675\u2013685","journal-title":"Clin Pharmacol Ther"},{"key":"BF02251286_CR18","first-page":"1","volume":"9","author":"LG Miller","year":"1989","unstructured":"Miller LG (1989) Phenylpropanolamine: a controversy unresolved. J Clin Psychopharmacol 9:1\u20133","journal-title":"J Clin Psychopharmacol"},{"key":"BF02251286_CR19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/02791072.1987.10472376","volume":"19","author":"JP Morgan","year":"1987","unstructured":"Morgan JP, Wesson DR, Puder KS, Smith DE (1987) Duplicitous drugs: the history and recent status of look-alike drugs. J Psychoact Drugs 19:21\u201331","journal-title":"J Psychoact Drugs"},{"key":"BF02251286_CR20","first-page":"150","volume-title":"Phenylpropanolamine: risks, benefits, and controversies","author":"JP Morgan","year":"1985","unstructured":"Morgan JP, Puder KS, Kagan DV (1985) The emergence of phenylpropanolamine in simulated controlled substances (look-alikes) after 1980. In: Morgan JP, Kagan DV, Brody JS (eds) Phenylpropanolamine: risks, benefits, and controversies. Praeger Scientific, New York, pp 150\u2013164"},{"key":"BF02251286_CR21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/978-1-4612-4812-5_16","volume-title":"Methods of assessing the reinforcing properties of abused drugs","author":"DA Overton","year":"1987","unstructured":"Overton DA (1987) Application and limitations of the drug discrimination method for the study of drug abuse. In: Bozarth MA (ed) Methods of assessing the reinforcing properties of abused drugs. Springer, New York Berlin Heidelberg London Paris Tokyo, pp 291\u2013340"},{"key":"BF02251286_CR22","first-page":"185","volume":"28","author":"Hl Silverman","year":"1980","unstructured":"Silverman Hl, Kreger BE, Lewis GP, Karabelas A, Paone R, Foley M (1980) Lack of side effects from orally administered phenylpropanolamine, and phenylpropanolamine with caffeine: a controlled three-phase study. Curr Ther Res, 28:185\u2013195","journal-title":"Curr Ther Res"},{"key":"BF02251286_CR23","first-page":"343","volume-title":"Phenylpropanolamine: risks, benefits, and controversies","author":"DE Smith","year":"1985","unstructured":"Smith DE (1985) Look-alike drugs and drugs of deception: epidemiological, toxicological, and clinical considerations. In: Morgan JP, Kagan DV, Brody JS (eds) Phenylpropanolamine: risks, benefits, and controversies. Praeger Scientific, New York, pp 343\u2013361"},{"key":"BF02251286_CR24","first-page":"275","volume-title":"Advances in behavioral pharmacology, vol 6. Neurobehavioral pharmacology","author":"WL Woolverton","year":"1987","unstructured":"Woolverton WL (1987) Analysis of drug interactions in behavioral pharmacology. In: Thompson, T, Dews, PB, Barrett JE (eds) Advances in behavioral pharmacology, vol 6. Neurobehavioral pharmacology. Lawrence Erlbaum Hillsdale, NJ, pp 275\u2013302"},{"key":"BF02251286_CR25","first-page":"926","volume":"237","author":"WL Woolverton","year":"1986","unstructured":"Woolverton WL, Johanson CE, Garza R de la, Ellis S, Seiden LS, Schuster CR (1986) Behavioral and neurochemical evaluation of phenylpropanolamine. J Pharmacol Exp Ther, 237:926\u2013930","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02251286.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02251286\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02251286","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T17:48:40Z","timestamp":1557942520000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02251286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,2]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1993,2]]}},"alternative-id":["BF02251286"],"URL":"https:\/\/doi.org\/10.1007\/bf02251286","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,2]]}}}